CorMedix Inc. is a biopharmaceutical company based in Bridgewater, NJ, dedicated to developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. Their primary focus is on reducing and treating infectious and inflammatory diseases, with a particular emphasis on catheter-related bloodstream infections (CRBSIs) in hemodialysis patients.
With a strong commitment to research and development, CorMedix has gained FDA approval for their product DefenCath, which is designed to reduce the incidence of CRBSIs in adult hemodialysis patients. The company's pipeline includes the development of other innovative therapeutic options, such as LOCK-IT-100 and taurolidine, aimed at addressing critical medical needs. Through their scientific advisory board and extensive publications, CorMedix strives to provide effective solutions for patients facing life-threatening conditions.
Generated from the website